thompson part 2 · tst: tuberculin skin test; igra: interferon gamma release assay. non-inferiority...

54

Upload: others

Post on 18-Jul-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,
Page 2: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

LookingForward…

• Howoftenwilldualtherapywithfragiledrugs(3TC,rilpivirine)leadtointegrase monotherapy?Tointegrase resistance?

• Howoftenwillresistanceemergeduringsubtherapeutic dosingwithlongactingdrugs?

Page 3: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

NEJM 2017; 377:1605-7

NN

RTI

Page 4: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

5.GenericART

WillTheyDecreaseCosts?

Page 5: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

GenericTDF/3TC

GenericEFV600mg/TDF/3TC

GenericRitonavir

GenericEFV400mg/TDF/3TC

LookingForward:DOR/gTDF/g3TC

Page 6: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Generics

Average Wholesale Price (AWP)

Wholesale Acquisition Cost (WAC)

Average Manufacturer Price (AMP) Nonfederal Average Manufacturer Price (Non-FAMP)

Federal Supply Schedule (FSS) Price

Federal Ceiling Price

Federal Ceiling; “Big 4” Price

Best Price

Medicaid Price340B Price

Private sector prices

Rebates to PBMsCopay assistance

Other price concessions

Unit rebate: 23.1% / 13% of AMP orAMP – Best Price plus

CPI penalties

76% of non-FAMP minus additional discounts

Supplemental rebates and discounts negotiated (including ADAPs)

Supplemental discounts negotiated (VA and DoD)

Negotiation on most-favored commercial customer price

DrugPricing:TheSimpleVersion

Federal Upper Limit

State Maximum Allowable Cost

Slide courtesy Tim Horn, ACTHIV 2018

Page 7: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Lookingforward…

• Highprices=notsustainable,butwillgenericshelp?• Lackofpricetransparency

Ø “Secret”discounts&rebates,olderdrugsarecheaperØ Expensivemiddlemen(PharmacyBenefitManagers-

PBMs)Ø Copaycardstoshieldpatientsbutkeeppriceshigh

• Drugaccessisafragile“HouseofCards”• Advocacyneededhere!

Page 8: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

And…

Page 9: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

UnintendedConsequences

• Decoupling of single tablet regimens can lead to desynchronization of med refills• “I couldn’t afford both copays, so I only got one of them this

time.”• Generic costs are not necessarily cheap

• Some insurers place all generics on the highest tier• Generics may not be covered by “copay cards” may cost

the patient more than the more “expensive” drug• “They told me that they wouldn’t cover my TruvadaTM since

there is now a generic. But the generic cost $300. I couldn’t afford it.”

Page 10: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

6.TBTreatmentforPeoplewithHIV

Gamechangerornot?

Page 11: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

BRIEF-TB/A5279 Study:1MonthofRifapentine/IsoniazidtoPreventTBinPeopleWithHIV

Swindells S, et al. 25th CROI. Boston, 2018. Abstract 37LB.

Phase 3 (n=2996)

Open-label• HIV infected (≥13 years of age)• No evidence of active TB with

either:• TST reactivity ≥5 mm

and/or + IGRA, OR• Live in high TB burden

area• Permitted ART while on

rifapentine• Efavirenz- or nevirapine-

based regimens

Week 0 4 36 156

*Rifapentine 450 mg/day (<45 kg) or 600 mg/day (≥45 kg). All patients received vitamin B6 (25 mg) with INH.TST: tuberculin skin test; IGRA: interferon gamma release assay.Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years, 62.5% of control event rate).

Rifapentine +Isoniazid 300

mg/day

Isoniazid 300 mg/day

No Treatment

No Treatment

1monthRifa/INHnon-inferiorto9monthsINHalone

Endpoints:TB,TBdeath,ordeathfromunknowncauses

Page 12: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

But…

Page 13: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Rifapentine (RPT)PK• InducesCYP3A4,thereforeinteractswithmostPIs,someINIs• DTGPKstudywithINH/RPTterminatedearlyduetotoxicity(2of3pts)

– Nausea,vomiting,fever,hypotensionrequiringhospitalization,grade2-4transaminaseelevation

• DTGexposuredecreased46%,Day14;Cmin decreased74%,Day15– OnesubjecthadmultipleCmin values<0.3μg/mL

Brooks K, et al. CROI 2017. Abstract 409a

Page 14: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

PKwithRifampinTAF/Rifampin:ProbablyOK• ImpactofrifampinonTVF-DP

plasmaconcentrations– TDF:decreased55%– TAF:decreased36%

• ImpactofrifampinonTVF-DPintracellularconcentrations– TDF:decreasedby40%– TAF:increasedby76%relative

toTDFwithoutrifampin• Nodatawithrifapentine

BIC/Rifampin: JustSayNo!• PlasmaBICconcentrations:

~60%lower• TroughBICconcentrations:

~80%lower• Twicedailydosingdoesnot

mitigatetheeffect• Nodatawithrifapentine but

wouldavoid

Cerrone M, et al. 25th CROI. Boston, 2018. Abstract 28LB. Custodio JM, et al. 25th CROI. Boston, 2018. Abstract 34.

Page 15: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

LookingForward:OptimalARTforTB?Newdrugs?

Page 16: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

7.TheOpioidEpidemic

NCHS data brief, no 282. Hyattsville, MD: National Center for Health Statistics. 2017.

Page 17: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

OpioidDeathsRise,EspeciallyinYouth15-19

Curtin SC, Tejada-Vera B, Warner M. Drug overdose deaths among adolescents aged 15–19 in the United States: 1999–2015. NCHS data brief, no 282. Hyattsville, MD: National Center for Health Statistics. 2017.

Page 18: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

NewClustersofHIVInfectionAssociatedwithIDU

https://www.cincinnati.com/story/news/2018/01/09/nky-cincinnati-see-sharp-rise-hiv-cases-linked-injected-drug-use-cdc-assist-nky/1012532001/

https://www.bostonglobe.com/metro/2017/12/16/uptick-hiv-among-injecting-drug-users-raises-fears-resurgent-epidemic/Mrzu1glhYosSGR3mVEEiLP/story.html

• NorthernKentucky:18cases(upfrom0to5/yr)• Cincinnati:126cases(upfrom91)• Massachusetts:78casesamongPWID,100%increase

http://www.bostonglobe.com/metro/2018/04/05/cdc-investigate-puzzling-surge-hiv-lawrence-lowell-among-injecting-drug-users/XHgt4NKAgdxVKgdzH8TZbI/story.html

April 5, 2018

Page 19: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

LookingForward…

• Remind lawmakers about ID complications of the opioid epidemicØ HIV, hepatitis B and CØ Infective endocarditisØ Skin and soft tissue infections

• Ryan White clinics need expansion funding to offer Medication Assisted Treatment

• Bills are pending on “The Hill.” Advocacy is urgently needed right now!

Page 20: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,
Page 21: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

8.TheSTDEpidemicCulture Clashes and Funding Deficits

Page 22: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

PrimaryandSecondarySyphilis— ReportedCasesbySexandSexualBehavior,36States*,2012–2016

*36stateswereabletoclassify≥70%ofreportedcasesofprimaryandsecondarysyphilisaseitherMSM†,MSW†,orwomenfor eachyearduring2012–2016.† MSM=Gay,bisexual,andothermenwhohavesexwithmen(collectivelyreferredtoasMSM);MSW=Menwhohavesexwithwomen only.

Page 23: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

PrimaryandSecondarySyphilis— ReportedCasesbySexandSexualBehavior,36States*,2012–2016

*36stateswereabletoclassify≥70%ofreportedcasesofprimaryandsecondarysyphilisaseitherMSM†,MSW†,orwomenfor eachyearduring2012–2016.† MSM=Gay,bisexual,andothermenwhohavesexwithmen(collectivelyreferredtoasMSM);MSW=Menwhohavesexwithwomenonly.

Bi

Benzathine Penicillin G Crisis

• Unavailable – sole source manufacturing chain = stock-outs

• Unaffordable – prices as high as $350 per dose, far exceeding reimbursement

Page 24: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

http://pittsburgh.cbslocal.com/2018/03/09/beaver-county-std-uptick/

Page 25: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

http://www.foxnews.com/health/2018/03/08/shock-in-milwaukee-over-new-outbreak-hiv-and-syphilis-including-babies-and-teens.html

• 125personswithHIV,syphilisorboth– 13%increaseinHIV;29%syphilis;12%gonorrhea

Page 26: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

GovernorScottWalkercutevidence-basedsexeducation,fundedabstinenceonlyprograms.

Page 27: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

The2018OmnibusfederalbudgetincreasedCDC’s2019STDbudgetby$5million(replacing

fundsthatwerepreviouslycut.)

Thiswasnotanaccident– thiswasadvocacy!LookingForward:Moreadvocacyneeded!

Page 28: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

• Ceftriaxone MIC of 0.5 mg/L • Azithromycin MIC of >256 mg/L (high-level azithromycin resistant, HLAziR)• Susceptible only to spectinomycin. • “This is the first global report of HLAziR N. gonorrhoeae which is also resistant to ceftriaxone.”

Public Health England, Health Protection Report Volume 12 Number 11

Looking Forward: With an accelerating STD epidemic, Bad Bugs are just a flight away from your clinic!

• Advocacy for state/federal STD clinic funding• Antimicrobial stewardship• New drugs needed!

Page 29: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

9.HealthPolicyThreatsACA,Medicaid,Medicare,RyanWhite,

PEPFAR,affordablemedicationsAllunderattack…

Page 30: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

BudgetBulletDodged(Temporarily)

CongressrejectedtheWhiteHouse’sbudgetthatwouldhave

– EliminatedRyanWhiteAETCsandSPNS– CutfundingforNIAIDby$111million– CutCDCfundingby$767million– SlashedfundingforPEPFAR,theGlobalFund,globalTBprograms

Thiswasnotanaccident– thiswasadvocacy!

Page 31: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,
Page 32: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

ThreatstothePatientProtectionandAffordableCareAct

• Marketinstability:eliminationofcostsharingreductionsresultsinhigherpremiums

• Waiversallowfinancialpenaltiesforpreexistingconditions• EliminationofEssentialHealthBenefits(prescriptiondrugs!)• Restorationoflifetimecapsonoutofpocketspending• Cheaper“junk”insurance:lowpremium,lowcoverage

Page 33: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Slide 33 of 79

ThreatstoContinuousAccesstoAffordableART

• Priorauthorizations• Step-therapy• 30dayquantitylimits• ARVplacedonhighesttiers,subjecttohighcoinsurance,aviolationoftheanti-discriminationclause,Section1557oftheACA

Page 34: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Slide 34 of 79

Page 35: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

CopayAccumulatorProgramsIncreasing

• Manufacturerco-paycardsnolongercounttowardapatient’sdeductibleorout-of-pocketmaximum

• Insurersusemisleadingterms:“CouponAdjustment:BenefitPlanProtectionprogram”or“OutofPocketProtectionProgram.”=FAKENEWS!

• Patientgetsstuckwithentiredeductible,makingARTunaffordableformanypeople.

Page 36: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

HOT! NewCMSBudgetGutsACA

https://www.cms.gov/About-CMS/Agency-Information/PerformanceBudget/Downloads/FY2019-CJ-Final.pdf, p10

Page 37: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

LookingForward…MoreoftheSame!KeepYourEyeontheFinePrint!

SpeakUp!

Page 38: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Speakup.hiv

Page 39: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

10.StigmaandDiscrimination

Page 40: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Ploumen L, Address at UN High Level Meeting on AIDS, June 9, 2016

Page 41: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

LeadershipMatters:VastlyDifferentRealities

VS

“Quarantine”

“Whatcanwelegallydo”

“...welltheyarecarriers,withthepotentialtospreadwhereasinthepasttheydiedmorereadily…notposingarisk

“ …firststateinthenationcommittedtoendingthisepidemic.”

SlidecourtesyCarlosdelRio,JonathanColasanti

Page 42: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

“ItwasonlywhenIlearnedaboutU=UthatIrealizedthatIhavebeenlivingforalltheseyearscarryingthisheavyweight.BecauseItookmymeds,Ikeptonliving.ButinsideIfeltlikeIwasdying.Andthatmademeafraidtogetclosetoanyoneelse.ThenightIheardaboutU=U,Icouldn’tstopcrying.ItwaslikethatburdenIdidn’tevenrealizeIwascarryingjustfellaway.”

Slide adapted from Robert Remien; CROI 2018

Page 43: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

AND…

• No White House Office of National AIDS Policy• Presidential Advisory Council on HIV/AIDS disbanded• National HIV/AIDS Strategy removed from White

House website

Page 44: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

But…there’smore…Emboldenedwhitesupremacy

PoliceviolenceReligiouspersecution

Anti-immigrant&anti-LGBTQhatecrimesVotersuppression

Page 45: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

WhyDoesThisMatter?

Page 46: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Wearecaughtinaninescapablenetworkofmutuality,tiedinasinglegarmentofdestiny.Whateveraffectsonedirectly,affectsallindirectly.

-MartinLutherKing,Jr

Why We Can’t Wait, 1963

Page 47: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

CivilRights- UnderAttack- WhatDoWeDo?

Page 48: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

ACTUP,FIGHTBACK

Page 49: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Slide 49 of 79

Page 50: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,
Page 51: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

“Our lives begin to end the day

we become silent about things that

matter” #MLK50

Page 52: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

ActivateYourInnerActivistMobilize,Organize,#Resist

Page 53: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

Acknowledgements

AppreciationforSlides,Data,Inspiration,Support• JonathanColasanti,CarlosdelRio– GradyIDP/Emory• Demetre Daskalakis,StaceyWilkins–NYCDOH• TimHorn• MichaelMugavero• Onyema Ogbuagu• RobertRemien• DawnSmith- CDC

Page 54: Thompson Part 2 · TST: tuberculin skin test; IGRA: interferon gamma release assay. Non-inferiority design: 1.25/100 person-years (ie, upper 95% CI of rate up to 3.25/100 person-years,

ACTUP,FIGHTBACK